angiogenesis related compound library

A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1283 endogenous metabolism-related compounds for research in endogenous metabolism-related diseases and drug screening.

A unique collection of 1940 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of 683 diabetes related compounds;

A unique collection of 1513 neurotransmitter receptor compounds, can be used for HTS and HCS screening；

A unique collection of 1408 cardiovascular diseases related compounds for high throughput screening (HTS) and high content screening (HCS);

A collection of 747 natural product molecules originated from Tibetan medicine, which can be used for high-throughput and high-content screening.

It is well-selected from Bioactive compound library Plus (D7800), from which 1-15 compounds with the highest scores (activity value, pharmacological properties, structure-diversity, etc.) were chosen. This library consists of 989 compounds without compro

A unique collection of 492 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 677 cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 3404 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 910 DNA Damage & Repair related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1544 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 4630 approved and clinical drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2427 of orally active compounds for high-throughput screening and high-content screening.

A unique collection of 1268 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS);

Well-chosen 953 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 3188 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 449 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening；

A unique collection of 1702 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study；

A unique collection of 334 nucleoside and nucleotide analogues, can be used for research and development of anti-viral, anti-tumor, anti-fungal, and anti-depressive drugs;

1066 types of active small molecules associated with pyroptosis for high-throughput and high-content screening.

791 peptides can be used in peptide drug development and signaling transduction and mechanism study;

A collection of 950 natural product molecules originated from Mongolian medicine, which can be used for high-throughput and high-content screening.

A unique collection of 1147 monomers from 60 TCM plants, a powerful tool for anti-COVID-19 drug discovery, can be used for HTS and HCS screening；

A unique collection of 1040 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening;

A unique collection of 2540 compounds targeting CNS signaling for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 7234 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 904 antibacterial bioactive compounds, a powerful tool for antibacterial drug development;

A unique collection of 812 promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine;

A unique collection of 1197 stem cell differentiation signaling targeted compounds for high throughput and high content screening;

A unique collection of 2247 anti-obesity compounds for high throughput and high content screening;

A collection of 17100 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

A unique collection of 250 compounds targeting chromatin remodeling pathway for high throughput screening (HTS) and high content screening (HCS);

702 glycometabolism-related comounds, can be used for HTS and HCT;

A unique collection of 784 compounds targeting endocrine system for high throughput screening (HTS) and high content screening (HCS) for new drugs;

Well-chosen 338 GPCR targeting compounds with unique structures;

A unique collection of 218 mouse metabolites, which can be used for HTS and HCS;

A unique collection of 268 compounds targeting serotonin receptors for high throughput screening and high content screening;

A unique collection of 701 preclinical compounds for high throughput screening (HTS) and high content screening (HCS);

128 methylation-related compounds that can be used for high-throughput and high-content screening.

A unique collection of 420 compounds targeting PI3K Akt mTOR signaling for research in PI3K Akt mTOR signaling, and drug discovery in diseases involved with PI3K Akt mTOR signaling;

A unique collection of 97 beta-lactam compounds, can be used in HTS and HCS;

A unique collection of 857 compounds with anti-PD activities or acting on main drug targets of PD can be used for HTS and HCS.

A unique collection of 986 compounds with anti-AD activities or acting on main drug targets of AD can be used for HTS and HCS.

530 non-steroidal anti-inflammatory compounds for high-throughput and high-content screening.

A unique collection of 779 ferroptosis signaling pathway related compounds, a powerful tool for new target identification, drug discovery, and mechanism study；

A unique collection of 514 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS);

Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species (ROS) and a biological system's ability to readily detoxify the reactive intermediates or repair the resulting damage. Disturbances in the normal redox state of cells can cause toxic effects through the production of peroxides and free radicals that damage all components of the cell, including proteins, lipids, and DNA. In humans, oxidative stress is thought to be involved in the development of atherosclerosis, heart failure, myocardial infarction, cancer, infection etc. Antioxidants are a class of compounds that counteract oxidative stress and reduce oxidative damage. The TargetMol Antioxidant Compound Library is a unique collection of 1314 small molecules with inhibitory effects on oxidative stress and is a useful tool for high-throughput screening and high-content screening in the study of oxidative stress.

A unique collection of 252 antifungal compounds effective for drug repurposing screening, combination screening and biological investigation.